Figure 2.

Publications employing patient-derived xenograft (PDX) or patient-derived organoids (PDO) for each cancer type, and their association with clinical trials. The proportion of papers published between 2014–2019 for breast, lung and colorectal cancers using PDX or PDO, relative to the total number of papers published for each cancer type, regardless of the technology used, and the papers associated with a clinical trial are shown. Blue bars indicate the proportion of papers using each technology, relative to the total number of papers for that specific cancer type, and orange bars indicate the proportion of papers associated with a clinical trial. Data were retrieved from PubMed as described in the Methods.